Arthneeti

Zenotech Laboratories Share Price & Earnings Call Analysis

₹38.08-0.68% today
Market cap
₹232 Cr
ROE
-1.15%
Price to sales
5.21
Debt to equity
0.00
52W high / low
₹53.0 / ₹34.3
Sales growth (5Y)
14.20%
EBITDA margin
17.02%
Net profit margin
-2.52%
Promoter holding
68.84%
Sales (last year)
₹45 Cr

Incorporated in 1989, Zenotech Laboratories Ltd is in the business of manufacturing biotechnology products[1]

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Zenotech Laboratories rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Zenotech Laboratories.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Zenotech Laboratories

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Zenotech Laboratories

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +10.989.2611.5310.949.119.919.7711.2412.139.6411.2312.869.89
Expenses +5.955.596.015.676.336.487.367.377.667.188.948.599.72
Operating Profit5.033.675.525.272.783.432.413.874.472.462.294.270.17
OPM %45.81%39.63%47.88%48.17%30.52%34.61%24.67%34.43%36.85%25.52%20.39%33.20%1.72%
Other Income +0.230.200.190.280.330.341.691.000.440.590.750.120.65
Interest0.000.000.000.000.000.000.000.000.000.000.000.000.00
Depreciation1.781.801.811.741.731.731.751.761.731.771.781.801.76
Profit before tax3.482.073.903.811.382.042.353.113.181.281.262.59-0.94
Tax %-5.17%29.95%27.18%11.55%51.45%37.25%42.55%45.66%61.32%22.66%165.87%25.48%235.11%
Net Profit +3.671.442.833.360.661.291.351.691.230.99-0.841.93-3.15
EPS in Rs0.600.240.460.550.110.210.220.280.200.16-0.140.32-0.52

Financials of Zenotech Laboratories

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +4.082.062.2511.1413.0326.0222.4536.5742.4240.8343.0543.61
Expenses +24.149.7312.6519.0116.5417.0416.0719.1121.7123.5628.8734.42
Operating Profit-20.06-7.67-10.40-7.87-3.518.986.3817.4620.7117.2714.189.19
OPM %-491.67%-372.33%-462.22%-70.65%-26.94%34.51%28.42%47.74%48.82%42.30%32.94%21.07%
Other Income +0.350.041.912.374.717.540.410.631.080.963.472.11
Interest6.657.557.502.450.120.891.551.220.110.000.000.00
Depreciation4.063.963.873.904.204.856.466.977.177.096.967.11
Profit before tax-30.42-19.14-19.86-11.85-3.1210.78-1.229.9014.5111.1410.694.19
Tax %0.00%0.00%0.00%0.00%0.00%0.00%0.00%-123.94%20.12%25.49%47.52%125.54%
Net Profit +-30.41-19.14-19.87-11.85-3.1310.78-1.2222.1811.598.305.61-1.07
EPS in Rs-4.99-3.14-3.26-1.94-0.511.77-0.203.631.901.360.92-0.18
Dividend Payout %0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials of Zenotech Laboratories

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital34.4334.4334.4361.0361.0361.0361.0361.0361.0361.0361.0361.03
Reserves-61.68-80.49-100.33-19.01-22.13-11.40-12.629.6121.2429.5135.1034.09
Borrowings +54.3254.2954.280.0020.2421.4220.666.000.000.000.000.00
Other Liabilities +36.6444.6962.3739.7225.4514.5116.7817.4518.6115.6614.9016.03
Total Liabilities63.7152.9250.7581.7484.5985.5685.8594.09100.88106.20111.03111.15
Fixed Assets +52.1348.1746.8344.4343.1148.7374.2370.9165.3865.5860.8762.29
CWIP0.000.000.002.3216.9529.082.180.284.981.963.573.60
Investments0.000.000.000.000.000.000.000.000.000.000.000.00
Other Assets +11.584.753.9234.9924.537.759.4422.9030.5238.6646.5945.26
Total Assets63.7152.9250.7581.7484.5985.5685.8594.09100.88106.20111.03111.15

Financials of Zenotech Laboratories

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-7.72-4.801.64-16.25-14.0411.385.7417.6720.6611.829.4910.20
Cash from Investing Activity +0.345.50-0.69-2.65-16.19-20.79-4.82-1.84-5.82-21.1515.27-6.49
Cash from Financing Activity +6.77-0.83-0.7246.8315.02-2.700.45-15.87-6.110.000.000.00
Net Cash Flow-0.60-0.130.2327.92-15.21-12.111.38-0.048.73-9.3324.763.71
Free Cash Flow-7.75-4.810.93-20.07-32.07-10.370.8315.7314.477.595.631.88
CFO/OP38%76%-15%203%387%130%92%107%106%75%81%105%

Financials of Zenotech Laboratories

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days35.7862.010.000.0066.1126.0961.7839.2228.5729.0563.1673.49
Inventory Days232.69305.45202.29374.12294.03
Days Payable222.42816.451,127.982,468.312,088.61
Cash Conversion Cycle46.05-448.99-925.69-2,094.19-1,728.4726.0961.7839.2228.5729.0563.1673.49
Working Capital Days-7,875.23-17,133.74-18,700.98-1,218.52-1,103.96-432.75-163.56-106.00-98.86-62.93-27.98-12.05
ROCE %-61.54%-65.67%-61.84%-5.93%8.14%0.47%15.26%18.35%12.94%9.40%4.59%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals